Roche Hldg Sp ADR (RHHBY)
$37.10
0.00 (0.00%)
RHHBY Stock Quote Delayed 30 Minutes
Our Stock Earnings Rundown – HSY KMB DFS SHW LUV TMO AMGN
A big week for earnings and dividend increases includes these 8 stocks in our portfolio.
Previous Close
$35.90
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
3.49M
Day's Range
$34.75 - $37.86
52-Week Range
$28.29 - $42.93
Dividend & Yield
$1.36 (3.67%)
RHHBY Stock Predictions, Articles, and Roche Hldg Sp ADR News
Biotech Movers: Keryx Jumps, Sarepta Slips
Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades.
Flu Season: Where Investors Can Find Relief
This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them.
Biotech Movers: A Tough Week All Around
Amarin Corp. slides on dashed buyout hopes, while Sarepta, Galena and others also faced serious setbacks.
Who Has the Best Pharma Pipeline?
A look through Big Pharma's drug pipelines shows a lot of promise across several companies, but one firm stands out as having big-time revenue growth potential.
Israel: Beyond the Risk, Opportunities Beckon
When you think of Israel, you probably think of conflict. But it has a strong economy and growing companies if you're willing to be a bit daring.
Pharma’s Q2 Earnings Lesson: The Big Picture Looks Good
The promising signs coming out of pharma this quarter doesn't mean you can just pick a stock out of a hat -- but it does mean a few are worth picking.
Novartis Wins Approval for Breast Cancer Drug
The FDA has granted approval for Novartis' drug Afinitor to be used as a treatment for breast cancer after it showed promise in clinical trials.
Medidata Solutions a Strong Buy in Cloud Computing
Medidata Solutions is a fast-growing cloud services provider to the health care industry that is poised for even better growth and is a buying opportunity
Nestle: A Global Dividend Powerhouse
Nestle is a world wide brand name that produces products, earnings, and dividends at a remarkable rate every year. Nestle is a great portfolio buy.
Obesity: The Next Investment Driver
The global market for weight-control products of all types is forecast to hit $53 billion in just five years, and several companies are primed to profit.
Feel Safe Scooping Up Swiss Stocks
There's a lot to like about Switzerland as an investment haven. It's not a perfect environment, but a number of Swiss stocks look promising right now.
Cue the Biotech M&A Attack!
A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.
3 New Biotech Buys for Your Portfolio
Three new biotech buys lead the way for additions to your portfolio as we head into April.
Analysts Run the Apple Asylum — Tuesday’s IP Market Recap
Price targets keep climbing to the moon: $715, $910 -- even $1,001.
Here Comes a Bidding War for Amylin
Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.
Generic Versions of Boniva Approved By the FDA
The FDA approved the first generic versions of osteoporosis drug Boniva, allowing manufacturers like Apotex, Orchid Healthcare and Mylan to make the drug.
Breaking Down Societe Generale’s Top 40 Dividend Stocks in the World
Societe Generale recently put out its annual list of the top 40 dividend payers across the globe. Here's a look at those companies, as well as a few trends.
Why Illumina’s Future Remains Bright
Rejection of Roche's takeover bid has cooled ILMN shares, but many expect Roche to step up its advances. If not, Illumina still has great growth prospects.
Amylin Gets a Boost From Its Diabetes Drug Approval
FDA approval of Bydureon -- a once-a-week injectable drug -- could make Amylin a takeover target for a Big Pharma.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
